Last reviewed · How we verify

Placebo-Metformin — Competitive Intelligence Brief

Placebo-Metformin (Placebo-Metformin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo-Metformin (Placebo-Metformin) — Steno Diabetes Center Copenhagen. Metformin reduces hepatic glucose production and improves insulin sensitivity, thereby lowering blood glucose levels in type 2 diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo-Metformin TARGET Placebo-Metformin Steno Diabetes Center Copenhagen marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
metformin+ gliclazide metformin+ gliclazide GlaxoSmithKline marketed Antidiabetic combination (biguanide + sulfonylurea) Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
Glimepiride/metformin fixed combination Glimepiride/metformin fixed combination Handok Inc. marketed Sulfonylurea/biguanide combination ATP-sensitive potassium channel (glimepiride); mitochondrial complex I / AMPK pathway (metformin)
metformin and rosiglitazone metformin and rosiglitazone New York Medical College marketed Antidiabetic combination (biguanide + thiazolidinedione) AMPK (metformin); PPAR-γ (rosiglitazone)
or Metformin HCl alone or Metformin HCl alone Bristol-Myers Squibb marketed Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
SGLT2i+Metformin+Linagliptin SGLT2i+Metformin+Linagliptin Huazhong University of Science and Technology marketed Combination antidiabetic agent (SGLT2 inhibitor + biguanide + DPP-4 inhibitor) SGLT2 transporter, mitochondrial complex I (metformin), dipeptidyl peptidase-4
MET + Vildagliptin Group MET + Vildagliptin Group Hospital de Clinicas de Porto Alegre marketed Combination antidiabetic agent (biguanide + DPP-4 inhibitor) Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo-Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-metformin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: